IAS 2019 — New drugs in a dual HIV treatment regimen show promise


  • Laura Vargas-Parada, Ph.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway 

  • Dual therapy with MK-8591 in combination with doravirine (DOR) was well-tolerated while participants achieved and maintained viral suppression among all treatment groups in study assessing efficacy and safety data. 

Why this matters 

  • MK-8591 (islatravir) is the first nucleoside reverse transcriptase translocation inhibitor in development for treatment of HIV-1 infection. 
  • DOR is a recently approved non-nucleoside reverse transcriptase inhibitor. 

Study design 

  • Phase 2B, double-blind, comparator-controlled, dose-ranging trial to evaluate efficacy and safety of MK-8591 with DOR. 
  • 121 patients (mean age, 31 years; 92.6% male, 76.0% white, 22% HIV-1 RNA >100,000 copies/mL) were randomly allocated to 1 of 4 study arms. 
    • First 24 weeks, equal number of patients received 1 of 3 doses of MK-8591 (0.25, 0.75, or 2.25 mg) plus DOR (100 mg) and 3TC (lamivudine; 300 mg) or DOR/3TC/TDF (tenofovir disoproxil) once daily with placebo. 
    • After 24 weeks, those on MK-8591 who achieved HIV-1 RNA
  • Efficacy endpoints included overall proportion of patients at week 48 with HIV-1 RNA
  • Safety was assessed by adverse event reporting.

Key results  

  • Proportion of patients achieving HIV-1 RNA
  • 0.25 mg, 89.7%; 
  • 0.75 mg, 90.0%; 
  • 2.25 mg, 77.4%; and 
  • With DOR/3TC/TDF, 83.9%. 
  • Mean change in CD4+ T-cell count was similar for all groups. 
  • No patient had HIV-1 RNA >200 copies/mL or documented resistance to study drugs. 
  • Adverse events reported: 
    • MK-8591, any dose (combined 7.8%).
    • DOR/3TC/TDF (19.4%).
  • Limitations

    • Conference presentation reported without peer review. 

    Expert comment 

    • “These are promising data that encouraged the company to move to a phase 3 trial to see how these results can confirm in a larger study site and also to assess this dual combination for therapy in the future providing novel options for people,” said Jean-Michel Molina, the study’s lead investigator from Paris Diderot University and Saint-Louis Hospital, during a press conference.